Catalytic Asymmetric Multicomponent Reactions

Multicomponent Reactions

Volumn , Issue , 2005, Pages 277-299

  Seayad, Jayasree ^a   List, Benjamin ^a  

^a MAX PLANCK INSTITUT FÜR KOHLENFORSCHUNG   (Germany)

Author keywords

Addition of alkylzincs; Alkyne nucleophils; Aza Morita Baylis Hillman reactions; Catalytic asymmetric multicomponent reactions; Domino Knoevenagel hetero Diels Alder type reactions; Mannich reactions; Multicomponent reactions; Passerini reaction; Strecker reaction; Three component aldolizations

Indexed keywords

EID: 84890734483     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527605118.ch9     Document Type: Chapter

References (199)

1. NSF report on "Societal implications of Nanoscience and Nanotechnology", March 2001
2. J. M. Nam, S. Park, C. A. Mirkin, Bio-barcodes based on oligonucleotide-modified nanoparticles, J. Am. Chem. Soc. 2002, 124, 3820-3821.
3. A. S. Lubbe, C. Alexiou, C. Bergermann, Clinical applications of magnetic drug targeting, J. Surg. Res. 2001, 95, 200-206.
4. L. Illum, A. E. Church, M. D. Butterworth, A. Arien, J. Whetstone, S. S. Davis, Development of systems for targeting the regional lymph nodes for diagnostic imaging: in vivo behavior of colloidal PEG-coated magnetite nanospheres in the rat following interstitial administration, Pharm. Res. 2001, 18, 640-645
5. L. K. Komissarova, A. A. Kuznetsov, N. P. Gluchoedov, M. V. Kutushov, M. A. Pluzan, Absorptive capacity of iron-based magnetic carriers for blood detoxification, J. Magn. Magn. Mater. 2001, 225, 197-201
6. Cancer Statistics, American Cancer Society, 2004
7. M. De Lena, C. Brambilla, A. Morabito, G. Bonadonna, Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate and 5-fluorouracil for advanced breast cancer, Cancer 1975, 35, 1108-1115.
8. J. M. Bull, D. C. Tormey, S. H. Li, P. P. Carbone, G. Falkson, J. Blom, E. Perlin, R. Simon, A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy, Cancer 1978, 41, 1649-1657.
9. R. J. Santen, Endocrine treatment of prostate cancer, J. Clin. Endocrinol. Metab. 1992, 75, 685-689.
10. J. L. Emmet, L. F. Greene, A. Papantoniou, Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies, J. Urol. 1960, 83, 471-484.
11. R. M. O'Regan, V. C. Jordan, Tamoxifen to raloxifene and beyond, Semin Oncol 2001, 28, 260-273.
12. S. A. Eccles, G. Box, W. Court, J. Sandle, C. J. Dean, Preclinical models for the evaluation of targeted therapies of metastatic disease, Cell Biophys. 1994, 24-25, 279-291.
13. K. Pantel, M. Otte, Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells, Semin. Cancer Biol. 2001, 11, 327-337.
14. C. J. Mettlin, G. P. Murphy, R. Ho, H. R. Menck, The National Cancer Database report on longitudinal observations on prostate cancer, Cancer 1996, 77, 2162-2166.
15. C. S. B. Galasko, The anatomy and pathways of skeletal metastases, in L. Weiss, A. H. Gilbert (eds.) Bone metastases, Boston, GK Hall, 1981, pp. 49-63.
16. K. Pantel, R. J. Cote, O. Fodstad, Detection and clinical importance of micrometastatic disease, J. Nat. Cancer Inst. 1999, 91, 1113-1124.
17. S. Honig, Hormonal therapy and chemotherapy, in J. R. Harris, M. E. Lippman, M. Morrow, S. Hellman (eds.) Diseases of the breast, Philadelphia, Lippincott-Raven Publishers, 1996, pp. 669-734.
18. S. Braun, and K. Pantel, Biological characteristics in micrometastatic cancer cells in bone marrow, Cancer Metastasis Rev. 1999, 18, 75-90.
19. M. Kavallaris, D. Y. Kuo, C. A. Burkhart, D. L. Regl, M. D. Norris, M. Haber, S. B. Horwitz, Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes, J. Clin. Invest. 1997, 100, 1282-1293.
20. M. Lehnert, S. Emerson, W. S. Dalton, R. de Giuli, S. E. Salmon, In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance, J. Natl. Cancer Inst. Mongr. 1993, 15, 63-67.
21. N. Baldini, K. Scotlandi, M. Serra, T. Shikita, N. Zini, A. Ognibene, S. Santi, R. Ferracini, N. M. Maraldi, Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution, Eur. J. Cell Biol. 1995, 68, 226-239.
22. A. Molinari, A. Calcabrini, S. Meschini, A. Stringaro, D. Del Bufalo, M. Cianfriglia, G. Arancia, Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells, Int. J. Cancer 1998, 75, 885-893.
23. J. Hamada, T. Tsuruo, Characterization of the ATPase activity of the 170 to 180 kilodalton membrane glycoprotein associated with multidrug resistance: the 170 to 180 kilodalton membrane glycoprotein is an ATPase, J.Biol. Chem. 1988, 263, 1454-1458.
24. R. Krishna, L. D. Mayer, Multidrug resistance (MDR) in cancer - mechanisms reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs, Eur. J. Cancer Sci. 2000, 11, 265-283.
25. J. C. Murray, J. Carmichael, Targeting solid tumours: challenges, disappointments and opportunities, Adv. Drug. Del. Rev. 1995, 17, 117-127.
26. R. K. Jain, Molecular regulation of vessel maturation, Nat. Med. 2003, 9, 685-93.
27. T. P. Padera, B. R. Stoll, J. B. Tooredman, D. Capen, E. di Tomaso, R. K. Jain, Pathology: cancer cells compress intratumour vessels, Nature 2004, 427, 695.
28. K. Weindel, J. R. Moringlane, D. Marme, H. A. Weich, Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? Neurosurgery 1994, 35, 439-449.
29. S. P. Olesen, Rapid increase in blood brain barrier permeability during severe hypoxia and metabolic inhibition, Brain Res. 1986, 368, 24-29.
30. S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, R. K. Jain, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment, Proc. Natl. Acad. Sci. USA 1998, 95, 4607-4612.
31. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D. A. Berk, V. P. Torchilin, R. K. Jain, Vasular permeability in human tumor xenograft: molecular size dependence and cut-off size, Cancer Res. 1995, 55, 3752-3756.
32. S. Unezaki, K. Maruyama, J. I. Hosoda, I. Nagae, Y. Koyanagi, M. Nakata, O. Ishida, M. Iwatsuru, S. Tsuchiya, Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy, Int. J. Pharm. 1996, 144, 11-17.
33. W. L. Monsky, D. Fukumura, T. Gohongi, M. Ancukiewcz, H. A. Weich, V. P. Torchilin, R. K. Jain, Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor, Cancer Res. 1999, 59, 4129-4135.
34. Y. Boucher, M. Leunig, R. K. Jain, Tumor angiogenesis and interstitial hypertension, Cancer Res. 1996, 56, 4264-4266.
35. G. Helmlinger, P. A. Netti, H. C. Lichtenbeld, R. J. Melder, R. K. Jain, Solid stress inhibits the growth of multicellular tumor spheroids, Nat. Biotechnol. 1997, 15, 778-783.
36. R. K. Jain, Transport of molecules in the tumor interstitium: a review, Cancer Res. 1987, 47, 3039-3051.
37. R. K. Jain, Barriers to drug delivery in solid tumors, Sci. Am. 1994, 271, 58-65.
38. P. E. Thorpe, F. J. Burrows, Antibody-directed targeting of the vasculature of solid tumors, Breast Cancer Res. Treat. 1995, 36, 237-251.
39. H. Maeda, The enhanced permeability and retention effect in tumor vasculature, the key role of tumor sensitive macromolecular drug targeting, Adv. Enzyme Regul. 2001, 41, 189-207.
40. H. Maeda, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release 2000, 65, 271-284.
41. P. Tartaj, M. Morales, S. Veintemillas Verdaguer, T. Gonzalez-Carreno, C. J. Serna, The preparation of magnetic nanoparticles for applications in biomedicine, J. Phys. D Appl. Phys. 2003, 36, R182-183
42. R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, R. Langer, Biodegradable long-circulating polymeric nanospheres, Science 1994, 263, 1600-1603.
43. S. M. Moghimi, A. C. Hunter, J. C. Murray, Long circulating and target specific nanoparticles: theory to practice, Pharm. Rev. 2001, 53, 283-218.
44. G. Storm, S. O. Belliot, T. Daemen, D. D. Lasic, Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system, Adv. Drug. Deliv. Rev. 1995, 17, 31-48.
45. J. Kreuter, Drug targeting with nanoparticles, Eur. J. Drug. Metab. Pharmacokinet. 1994, 19, 253-256.
46. L. Araujo, R. Lobenberg, and J. Kreuter, Influence of the surfactant concentration of the body distribution of nanoparticles, J. Drug. Target 1999, 6, 373-385.
47. V. Lenaerts, J. F. Nagelkerke, T. J. Van Berkel, P. Couvreur, L. Grislain, M. Roland, P. Speiser, In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchymal cells, J. Pharm. Sci. 1984, 73, 980-982.
48. P. Couvreur, B. Kante, V. Lenaerts, V. Scailteur, M. Roland, P. Speiser, Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles, J. Pharm. Sci. 1980, 69, 199-202.
49. A. Chonn, S. C. Semple, P. R. Cullis, Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo, Biochim. Biophys. Acta 1991, 1070, 215-222.
50. F. Yuan, Transvascular drug delivery in solid tumors, Semin. Radiat. Oncol. 1998, 8, 164-175, 1998.
51. Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike, H. Maeda, Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues, Jpn. J. Cancer Res. 1998, 89, 307-314.
52. R. Weissleder, H. C. Cheng, A. Bogdanova, A. Bogdanov Jr., Magnetically labeled cells can be detected by MR imaging, J. Magn. Reson. Imaging 1997, 7, 258-263.
53. T. C. Yeh, W. Zhang, S. T. Ildstad, C. Ho, Intracellular labeling of T-cells with superparamagnetic contrast agents, Magn. Reson. Med. 1993, 30, 617-625.
54. U. Schoepf, E. M. Marecos, R. J. Melder, R. K. Jain, R. Weissleder, Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies, Biotechniques 1998, 24, 642-646, 648-651.
55. A. Moore, J. P. Basilion, E. A. Chiocca, R. Weissleder, Measuring transferrin receptor gene expression by NMR imaging, Biochim. Biophys. Acta 1998, 1402, 239-249.
56. J. Panyam,W. Z. Zhou, S. Prabha, S. K. Sahoo, V. Labhasetwar, Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery, FASEB J. 2002, 16, 1217-26.
57. T. T. Shen, A. Bodganov, A. Bogdanov, K. Poss, T. J. Brady, R. Weissleder, Magnetically labeled secretin retains receptor affinity to pancreas acinar cells, Bioconjug. Chem. 1996, 7, 311-316.
58. D. Portet, B. Denizot, E. Rump, J. J. Lejeune, P. Jallet, Nonpolymeric coatings of iron oxide colloids for biological use as magnetic resonance imaging contrast agents, J. Coll. Interface Sci. 2001, 238, 37-42.
59. I. Brigger, C. Dubernet, P. Couvreur, Nanoparticles in cancer therapy and diagnosis, Adv. Drug. Del. Rev. 2002, 54, 631-651.
60. L. M. Lacava, Z. G. Lacava, M. F. Da Silva, O. Silva, S. B. Chaves, R. B. Azevedo, F. Pelegrini, C. Gansau, N. Buske, D. Sabolobic, P. C. Morais, Magnetic resonance of a dextran coated magnetic fluid intravenously administered in mice, Biophys. J. 2001, 80, 2483-2486.
61. A. E. Hawley, L. Illum, S. S. Davis, Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake, Pharm. Res. 1997, 14, 657-661.
62. A. E. Hawley, L. Illum, S. S. Davis, Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block copolymers, FEBS Lett. 1997, 400, 319-323.
63. G. Schwab, C. Chavney, Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated HA-RAS-mediated cell-proliferation and tumoricenicity in nude mice, PNAS 1994, 91, 10460-10464.
64. G. Blume, G. Cevc, Liposomes for the sustained drug release in vivo, Biochim. Biophys. Acta 1990, 1029, 91-97.
65. R. L. Hong, C. J. Huang, Y. L. Tseng, V. F. Pang, S. T. Chen, J. J. Liu, F. H. Chang, Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor bearing mice: Is surface coating with polyethylene glycol beneficial? Clin. Cancer Res., 1999, 5, 3645-3652.
66. K. Moribe, K. Maruyama, M. Iwatsuru, Estimation of surface state of poly(ethylene glycol)-coated liposomes using an aqueous twophase partitioning technique, Chem. Pharm. Bull. (Tokyo) 1997, 45, 1683-1687.
67. H. Ishiwata, S. B. Sato, S. Kobayashi, M. Oku, A. Vertut-Doi, K. Miyajima, Poly(ethylene glycol) derivative of cholesterol reduces binding step of liposome uptake by murine macrophage-like cell line J774 and human hepatoma cell line HepG2, Chem. Pharm. Bull. (Tokyo) 1998, 46, 1907-1913.
68. J. Lode, I. Fichtner, J. Kreuter, A. Berndt, J. E. Diederichs, R. Reszka, Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-polymethylmethacrylate nanoparticles in experimental tumor models, Pharm. Res. 2001, 18, 1613-1619.
69. D. Bazile, C. Prud'homme, M. T. Bassoulet, M. Marlard, G. Spenlehauer, M. Veillard, Stealth Me PEG-PLA nanoparticles avoid uptake by mononuclear phagocyte system, J. Pharm. Sci. 1995, 84, 493-498.
70. M. T. Peracchia, C. Vauthier, Puisieux, P. Couvreur, Development of sterically stabilized poly isobutyl 2 cyano acrylate nanoparticles by chemical coupling of poly ethylene glycol, J. Biomed. Mater. Res. 1997, 34, 317-326.
71. M. T. Peracchia, C. Vauthier, D. Desmaele, A. Gulik, J. C. Dedieu, M. Demoy, J. d'Angelo, P. Couvreur, Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate hexadecyl cyanoacrylate amphiphilic copolymer, Pharm. Res. 1998, 15, 550-556.
72. D. Sharma, T. P. Chelvi, J. Kaur, K. Chakravorty, T. K. De, A. Maitra, R. Ralhan, Novel taxol formulation: polyvinyl-pyrrolidone nanoparticles encapsulated taxol for drug delivery in cancer therapy, Oncol. Res. 1996, 8, 281-286.
73. S. Mitra, U. Gaur, P. C. Gosh, A. N. Maitra, Tumor targeted delivery of encapsulated dextra-doxorubicin conjugate using chitosan nanoparticles as carrier, J. Control Release 2001, 74, 317-323.
74. C. Verdun, F. Brasseur, H. Vranckx, P. Couvreur, M. Roland, Tissue distribution of doxorubicin associated with polyheylcyanoacrylate nanoparticles, Cancer Chemother. Pharmacol. 1990, 26, 13-18.
75. P. Couvreur, B. Kante, V. Lenaerts, V. Scailteur, M. Roland, P. Speiser, Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles, J. Pharm. Sci. 1980, 69, 199-202
76. S. Gibaud, J. P. Andreux, C. Weingarten, M. Renard, P. Couvreur, Increased bone marrow toxicity of doxorubicin bound to nanoparticles, Eur. J. Cancer A 1994, 30, 820-826.
77. P. Couvreur, G. Couarraze, J. P. Devissaguet, F. Puisieux, Nanoparticles: preparation and characterization, in Benita S (ed) Microencapsulation: methods and industrial application, Marcel Dekker, New York, 1996, pp. 183-211.
78. D. A. LaVan, T. McGuire, R. Langer, Small scale systems for in vivo drug delivery, Nature Biotech. 2003, 21, 1184-1191.
79. S. M. Moghimi, A. C. Hunter, J. C. Murray, Long circulating and target specific nanoparticles: theory to practice, Pharm. Rev. 2001, 53, 283-218.
80. C. Damge, C. Mitchel, M. Aprahamian, P. Couvreur, J. P. Devissaguet, Nanocapsules as carriers for oral peptide delivery, J. Control Release 1990, 13, 233-239.
81. Y. Nishioka, H. Yoshino, Lymphatic targeting with nanoparticulate system, Adv. Drug. Delivery Rev. 2001, 47, 55-64.
82. K. Yang, Y. Wen, L. Li, C. Wang, S. Hou, C. Li, Preparation of cucurbitacinBE polylactic acid nano-particles for targeting cervical lymph nodes, Hua Xi Kou Qiang Yi Xue Za Zhi 2001, 19, 347-50.
83. K. Yang, Y. Wen, L. Li, C. Wang, X. Wang, Acute toxicity and local stimulate test of cucurbitacinBE polylactic acid nano-particles of targeting cervical lymph nodes, Hua Xi Kou Qiang Yi Xue Za Zhi 2001, 19, 380-382.
84. F. Shikata, H. Tokumitsu, H. Ichikawa, Y. Fukumori, In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer, Eur. J. Pharm. Biopharm. 2002, 53, 57-63.
85. H. Tokumitsu, J. Hiratsuka, Y. Sakurai, T. Kobayashi, H. Ichikawa, Y. Fukumori, Gadolinium neutron-capture therapy using novel gadopentetic acid-chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor, Cancer Lett. 2000, 150, 177-82.
86. T. Watanabe, H. Ichikawa, M. Fukumori, Tumor accumulation of gadolinium in lipid nanoparticles intravenously injected for neutron capture therapy in cancer, Eur. J. Pharm. Biopharm. 2002, 54, 119-124.
87. N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, Y. Sugiyama, K. Nishio, Y. Matsumura, K. Kataoka, Novel cisplatinincorporated polymeric micelles can eradicate solid tumors in mice, Cancer Res. 2003, 63, 8977-8983.
88. R. Reszka, P. Beck, I. Fichtner, M. Hentschel, L. Richter, J. Kreuter, Body distribution of free, liposomal and nanoparticles associated mitoxantrone in B16 melanoma bearing mice, J. Pharmacol. Exp. Ther. 1997, 280, 232-237.
89. A. E. Gulyaev, S. E. Gelperina, I. N. Skidan, A. S. Antropov, G. Y. Kivman, J. Kreuter, Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles, Pharm. Res. 1999, 16, 1564-1569.
90. J. Kreuter, Nanoparticulate systems for brain delivery of drugs, Adv. Drug. Deliv. Rev. 2000, 47, 65-81.
91. I. Brigger, J. Morizet, G. Aubert, H. Chacun, M. J. Terrier-Lacombe, P. Couvreur, G. Vassal, Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting, J. Pharmacol. Exp. Ther. 2002, 303, 928-936.
92. H. Onishi, Y. Machida, Y. Machida, Antitumor properties of irinotecan containing nanoparticles prepared using poly(DL-lactic) acid and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol), Biol. Pharm. Bull. 2003, 26, 116-119.
93. C. Fonseca, S. Simoes, R. Gaspar, Paclitaxel loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity, J. Control Release 2002, 83, 273-286.
94. Z. Lu, T. H. Yeh, M. Tsai, J. Au, G. M. Wientjes, Paclitaxel loaded gelatin nanoparticles for intravesical bladder cancer therapy, Proc. Am. Assoc. Cancer Res. 2003, 44, 3675.
95. E. Tatou, C. Mossiat, V. Maupoil, F. Gabrielle, M. David, L. Rochette, Effects of cyclosporin and cremophor on working rat heart and incidence of myocardial lipid peroxidation, Pharmacology 1996, 52, 1-7.
96. R. T. Dorr, Pharmacology and toxicology of Cremophor EL diluent, Ann. Pharmacother. 1994, 28, S11-S14.
97. P. Mankad, J. Spatenka, Z. Slavik, G. Oneil, A. Chester, M. Yacoub, Acute effects of cyclosporine and cremophor EL on endothelial function and vascular smooth muscle in the isolated rat-heart, Cardiovasc. Drug. Ther. 1992, 6, 77-83.
98. L. Mu, S. S. Feng, A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS, J. Control Release 2003, 86, 33-48.
99. P. L. Weiden, J. Pratt, G. Brand, Tocosol paclitaxel (vitamin E paclitaxel emulsion): multicenter phase 2A studies with weekly dosing in non small cell lung, bladder, ovarian and colorectal cancers, Proc. Am. Assoc. Cancer Res. 2003, 44, # R 3665.
100. N. K. Ibrahim, N. Desai, S. Legha, P. Soon-Shiong, R. L. Theriault, E. Rivera, B. Esmaeli, S. E. Ring, A. Bedikian, G. N. Hortobagyi, J. A. Ellerhorst, Phase I and pharmacokinetic study of ABI-007, a cremophor free protein stabilized nanoparticles formulation of paclitaxel, Clin. Cancer Res. 2002, 8, 1038-1044.
101. N. Desai, T. De, A. Yang, B. Beals, P. Soon-Shiong, Pulmonary delivery of a novel cremophor free proteinbased nanoparticle preparation of paclitaxel, Proc. Am. Assoc. Cancer Res. 2003, 44, # 3672.
102. N. Desai, T. De, A. Yang, B. Beals, V. Trieu, P. Soon-Shiong, Pulmonary delivery of a novel cremophor free proteinbased nanoparticle preparation of paclitaxel, Proc. Am. Assoc. Cancer Res. 2003, 44, # 3673.
103. J. S. Chawla, M. M. Amiji, Biodegradable poly(e-caprolactone) nanoparticles for tumortargeted delivery of tamoxifen, Internat. J. Pharmaceutics 2002, 249, 127-138.
104. T. Ameller, V. Marsaud, P. Legrand, R. Gref, J. M. Renoir, In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668, Int. J. Cancer 2003, 106, 446-454.
105. R. K. Gilchrist, R. Medal, W. Shorey, R. C. Hanselman, J. C. Parrott, C. B. Taylor, Selective inductive heating of lymph nodes, Ann. Surg. 1957, 146, 596-606.
106. A. E. Merbach, E. Toth, The chemistry of contrast agents, in: Medical magnetic resonance imaging, Chichester, Wiley, 2001.
107. A. S. Luebbe, C. Bergeman, H. Riess, F. Schriever, P. Reichardt, K. Possinger, M. Matthia, B. Doerken, F. Herrmann, R. Guertler, P. Hohenberger, N. Haas, R. Sohr, B. Sander, A. Lemke, D. Ohlendorf, W. Huhnt, D. Huhn, Clinical experiences with magnetic drug targeting: A Phase I study with 4-epidoxorubicin in 14 patients with advanced solid tumors, Cancer Res. 1996, 56, 4686-4693.
108. B. R. Bacon, D. D. Stark, C. H. Park, S. Saini, E. V. Groman, P. F. Hahn, C. C. Compton, J. T. Ferrucci Jr., Ferrite particles: a new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatotoxicity after intravenous administration, J. Lab. Clin. Med. 1987, 110, 164-171.
109. M. G. Harisinghani, J. Barentsz, P. F. Hahn, W. M. Deserno, S. Tabatabaei, C. H. van de Kaa, J. de la Rosette, R. Weissleder, Noninvasive detection of clinically occult lymph-node metastases in prostate cancer, N. Engl. J. Med. 2003, 348, 2491-2499.
110. A. Senyei, K. Widder, C. Czerlinski, Magnetic guidance of drug carrying microspheres, J. Appl. Phys. 1978, 49, 3578-3583.
111. P. A. Voltairas, D. I. Fotiadis, L. K. Michalis, Hydrodynamics of magnetic drug targeting, J. Biomech. 2002, 35, 813-821.
112. A. S. Luebbe, C. Bergemann, W. Huhnt, T. Fricke, H. Riess, J. W. Brock, D. Huhn, Preclinical experiences with magnetic drug targeting: tolerance and efficacy, Cancer Res. 1996, 56, 4694-4701.
113. C. Alexiou,W. Arnold, R. J. Klein, F. G. Parak, P. Huhn, C. Bergemann, W. Erhardt, S. Wagenpfeil, A. S. Luebbe, Locoregional cancer treatment with magnetic drug targeting, Cancer Res. 2000, 60, 6641-6648.
114. C. Alexiou, R. Jurgons, R. J. Schmid, C. Bergemann, J. Henke, W. Erhardt, E. Huenges, F. Parak, Magnetic drug targeting - biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment, J. Drug Target 2003, 11, 139-149.
115. A. Moore, E. Marecos, A. Bogdanow, R. Weissleder, Tumoral distribution of long circulating dextran coated iron oxide nanoparticles in anrodent model, Radiology 2000, 214, 568-574.
116. S. Goodwin, C. Peterson, C. Hob, C. Bittner, Targeting and retention of magnetic targeted carrier (MTC) enhancing intra arterial chemotherapy, J. Magn. Magn. Mater. 1999, 194, 132-139.
117. S. Goodwin, C. A. Bittner, C. L. Peterson, G. Wong, Single dose toxicity study of hepatic intra arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier, Toxicol. Sci. 2001, 60, 177-183.
118. A. S. Luebbe, C. Bergemann, J. Brock, and D. G. McClure, Physiological aspects in magnetic drug targeting, J. Magn. Magn. Mater. 1999, 194, 149-155.
119. S. K. Pulfer, S. L. Ciccotto, J. M. Gallo, Distribution of small magnetic particles in brain tumor bearing rats, J. Neurol. Oncol. 1999, 41, 99-105.
120. T. Kubo, T. Sugita, S. Shimose, Y. Nitta, Y. Ikuta, T. Murakami, Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma bearing hamsters, Int. J. Oncol. 2000, 17, 309-315.
121. T. Kubo, T. Sugita, S. Shimose, Y. Nitta, Y. Ikuta, T. Murakami, Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters, Int. J. Oncol. 2001, 18, 121-126.
122. M. O. Oyewumi, R. J. Mumper, Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy, Bioconjug. Chem. 2002, 13, 1328-1335.
123. Y. Zhang, N. Kohler, M. Zhang, Surface modification of superparamagnetite nanoparticles and their intracellular uptake, Biomaterials 2002, 23, 1553-1561.
124. K. Na, T. Bum Lee, K. H. Park, E. K. Shin, Y. B. Lee, H. K. Choi, Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anticancer drug delivery system, Eur. J. Pharm. Sci. 2003, 18, 165-173.
125. Y. Rabin, Is intracellular hyperthermia superior to extracellular hyperthermia in the thermal sense? Int. J. Hyperthermia 2002, 18, 194-202.
126. A. M. Granov, O. V. Muratov, V. F. Frolov, Problems in the local hyperthermia of inductively heated embolized tissues, Theoretical Foundations of Chem. Engin. 2002, 36, 63-66.
127. W. J. Atkinson, I. A. Brezpvich, D. P. Chakraborty, Usable frequencies in hyperthermia with thermal seeds, IEEEE Trans. Biomed. Eng. BME 1984, 31, 70-75
128. E. Fattal, C. Vauthier, I. Aynie, Y. Nakada, G. Lambert, C. Malvy, P. Couvreur, Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides, J. Control Release 1998, 53, 137-143.
129. I. Aynie, C. Vauthier, H. Chacun, E. Fattal, P. Couvreur, Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense, Nucleic Acid Drug Dev. 1999, 9301-9312.
130. G. Lambert, E. Fattal, H. Pinto-Alphandary, A. Gulik, P. Couvreur, Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides, Pharm. Res. 2000, 17, 707-714.
131. G. Liu, D. Li, M. K. Pasumarthy, T. H. Kowalczyk, C. R. Gedeon, S. L. Hyatt, J. M. Payne, T. J. Miller, P. Brunovskis, T. L. Fink, O. Muhammad, R. C. Moen, R. W. Hanson, M. J. Cooper, Nanoparticles of compacted DNA transfect postmitotic cells, J. Biol. Chem. 2003, 278, 32578-32586.
132. D. M. Lynn, D. G. Anderson, D. Putnam, R. Langer, Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library, J. Am. Chem. Soc. 2001, 123, 8155-8156.
133. J. Panyam,W. Z. Zhou, S. Prabha, S. K. Sahoo, V. Labhasetwar, Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery, FASEB J. 2002, 16, 1217-1226.
134. C. Mah, I. Zolotukhin, T. J. Fraites, J. Dobson, C. Batich, B. J. Byrne, Microsphere mediated delivery of recombinant AAV vectors in vitro and in vivo, Mol. Ther. 2000, 1S, 239.
135. C. Mah, T. J. Fraites, I. Zolotukhin, S. Song, T. R. Flotte, J. Dobson, C. Batich, B. Byrne, Improved method of recombinant AAV2 delivery for systemic targeted gene therapy, Mol. Ther. 2002, 6, 106-112.
136. J. D. Hood, M. Bednarski, R. Frausto, S. Guccione, R. A. Reisfeld, R. Xiang, D. A Cheresh, Tumor regression by targeted gene delivery to the neovasculature, Science 2002, 296, 2404-2407.
137. L. Xu, P. Frederik, K. Pirollo, W. H.Tang, A. Rait, L. M. Xiang, W. Huang, I. Cruz, Y. Yin, E. Chang, Self-assembly of a virusmimicking nanostructure system for efficient tumor targeted gene delivery, Human Gene Ther. 2002, 13, 469-481.
138. M. Hiraoka, S. Jo, K. Akuta, Y. Nishimura, M. Takahashi, M. Abe, Radiofrequency capacitive hyperthermia for deep-seated tumors. II. Effects of thermoradiotherapy, Cancer 1987, 60, 128-135.
139. R. Cavaliere, E. C. Ciocatto, B. C. Giovanella, C. Heidelberger, R. O. Johnson, M. Margottini, B. Mondovi, G. Moricca, A. Rossi-Fanelli, Selective heat sensitivity of cancer cells. Biochemical and clinical studies, Cancer 1967, 20, 1351-1381.
140. P. Wust, B. Hildebrandt, G. Sreenivasa, B. Rau, J. Gellermann, H. Riess, R. Felix, P. M. Schlag, Hyperthermia in combined treatment of cancer, Lancet Oncol. 2002, 3, 487-497.
141. A. Jordan, R. Scholz, P. Wust, H. Faehling, R. Felix, Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles, J. Magn. Magn. Mater. 1999, 201, 413-419.
142. I. Hilger, R. Hergt, W. A. Kaiser, Effects of magnetic thermoablation in muscle tissue using iron oxide particles: an in vitro study, Invest. Radiol. 2000, 35, 170-179.
143. M. Shinkai, M. Matsui, T. Kobayashi, Heat properties of magnetoliposomes for local hyperthermia, Jpn. J. Hypertherm. Oncol. 1994, 10, 168-177
144. R. Hiergeist, W. Andrae, N. Buske, R. Hergt, I. Hilger, U. Richter, W. Kaiser, Application of magnetite ferrofluids for hyperthermia, J. Magn. Magn. Mater. 1999, 201, 420-422.
145. I. Hilger, K. Fruhauf, W. Andra, R. Hiergeist, R. Hergt, W. A. Kaiser, Heating potential of iron oxides for therapeutic purposes in interventional radiology, Acad. Radiol. 2002, 9, 198-202.
146. R. E. Rosenzweig, Heating magnetic fluid with alternating magnetic field, J. Magn. Magn. Mater. 2002, 252, 370-374.
147. A. V. Brusentsov, V. V. Gogosov, T. N. Buntsova, A. V. Sergeev, N. Y. Jurchenko, A. Kuznetsow, O. Kuznetsow, L. I. Shumakov, Evaluation of ferromagnetic fluids and suspensions for the site-specific radiofrequencyinduced hyperthermia of MX11 sarcoma cells in vitro, J. Magn. Magn. Mater. 2001, 225, 113-119.
148. A. Jordan, R. Scholz, P. Wust, H. Fahling, J. Krause, W. Wlodarczyk, B. Sander, T. Vogl, R. Felix, Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo, Int. J. Hypertherm. 1997, 13, 587-605.
149. R. T. Gordon, J. R. Hines, D. Gordon, Intracellular hyperthermia. A biophysical approach to cancer treatment via intracellular temperature and biophysical alterations, Med. Hypoth. 1979, 5, 83-102.
150. Q. A. Pankhurst, J. Connolly, S. K. Jones, J. Dobson, Applications of magnetic nanaoparticles in biomedicine, J. Phys. D Appl. Phys. 2003, 36, R167-R181.
151. M. Shinkai, B. Le, H. Honda, K. Yoshikawa, K. Shimizu, S. Saga, T. Wakabayashi, J. Yoshida, T. Kobayashi, Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes, Jpn. J. Cancer Res. 2001, 92, 1138-1145.
152. A. Ito, M. Shinkai, H. Honda, T. Kobayashi, Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy, Cancer Gene Ther. 2001, 8, 649-654.
153. E. J. Bergey, L. Levy, X. Wang, L. J. Krebs, M. Lal, K. S. Kim, S. Pakatchi, C. Liebow, P. N. Prasad, DC magnetic field induced magnetocytolysis of cancer cells targeted by LH-RH magnetic nanoparticles in vitro, Biomed. Microdevices. 2002, 4, 293-299.
154. L. R. Hirsch, R. J. Stafford, J. A. Bankson, S. R. Sershen, B. Rivera, R. E. Price, J. D. Hazle, N. J. Halas, J. L. West, Nanoshellmediated near-infrared thermal therapy of tumors under magnetic resonance guidance, Proc. Natl. Acad. Sci. USA 2003, 100, 13549-13554.
155. C. Loo, A. Lin, L. Hirsch, M. H. Lee, J. Barton, N. Halas, J. West, R. Drezek, Nanoshellenabled photonics-based imaging and therapy of cancer, Technol. Cancer Res. Treat. 2004, 3, 33-40.
156. A. M. Granov, O. V. Muratov, V. F. Frolov, Problems in the local hyperthermia of inductively heated embolized tissues, Theoretical Foundations of Chem. Engin. 2002, 36, 63-66.
157. W. J. Atkinson, I. A. Brezpvich, D. P. Chakraborty, Usable frequencies in hyperthermia with thermal seeds, IEEEE Trans. Biomed. Eng. BME 1984, 31, 70-75.
158. J. T. Santini Jr., A. C. Richards, R. Scheidt, M. J. Cima, R. Langer, Microchips as controlled drug-delivery devices, Angew. Chem. Int. Ed. 2000, 39, 2396-2407.
159. J. Kost, R. Langer, Responsive polymeric delivery systems, Adv. Drug Deliv. Rev. 1991, 6, 19-50.
160. J. T. Santini Jr., M. J. Cima, R. Langer, A controlled-release microchip, Nature 1999, 397, 335-338.
161. R. Scheidt, A. Richards, A. Rosenberg, A. Johnson, G. Voskerician, J. Anderson, R. Langer, M. J. Cima, MEMS-based microdelivery of drugs. Proceedings, 28th international symposium on controlled release of bioactive materials and 4th consumer and diversified products conference, San Diego, 2002, 1, 59-60.
162. E. E. Bakken, K. Heruth, Temporal control of drugs: an engineering perspective, Ann. NY Acad. Sci. 1991, 618, 422-427.
163. R. Langer, Drug delivery: drugs on target, Science 2001, 293, 58-59.
164. E. R. Edelman, J. Kost, H. Bobeck, R. Langer, Regulation of drug release from polymer matrixes by oscillating magnetic fields, J. Bio. Med. Res. 1985, 19, 67-83.
165. M. Shalaby, W. Shalaby, Implantable insulin controlled release systems for treating diabetes mellitus, Absorb. Biodegrad. Polymers 2004, 205-226.
166. G. M. Steil, A. E. Panteleon, K. Rebrin, Closed-loop insulin delivery - the path to physiological glucose control, Adv. Drug. Deliv. Rev. 2004, 56, 125-144.
167. C. Zion Todd, Y. Ying Jackie, Glucose-responsive nanoparticles for controlled insulin delivery. AIChE Annual Meeting, Conference Proceedings, San Francisco, 2003, pp. 112-119.
168. A. J. Coury, C. M. Philbrook, K. C. Skinner, Controlled release of antiarrhythmic agents from polymer hydrogels, PCT Int. Appl. 2004, 56 pp. CODEN: PIXXD2 WO 2004002449 A1 20040108 CAN 140:82260 AN 2004:20465 CAPLUS.
169. K. K. Midha, M. Hirsh, W. Lo, Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent, US Pat. Appl. Publ. 2002, 19 pp. Cont.-in-part of US Ser. No. 639,584.
170. A. Juppo, Novel modified-release formulation containing amphiphilic lipids as a hydrophobic matrix former. PCT Int. Appl. 2002. 31 pp. CODEN: PIXXD2 WO 2002064121 A1 20020822 CAN 137:190729 AN 2002:637506 CAPLUS.
171. V. C. Stevens, J. E. Powell, A. E. Lee, P. T. P. Kaumaya, D. H. Lewis, M. Rickey, T. J. Atkins, Development of a delivery system for a birth control vaccine using biodegradable microspheres, Proc. 19th Int. Symp. Controlled Release Bioact. Mater. 1992, 112-113.
172. E. D. B. Johansson, R. Sitruk-Ware, New delivery systems in contraception: vaginal rings, Am. J. Obstet Gynecol. 2004, 190, S54-S59.
173. D. Ausiello, J. T. Santini Jr., S. J. Herman, J. H. Prescott, Method and device for the controlled delivery of parathyroid hormone, PCT Int. Appl. 2004, 42 pp. CODEN: PIXXD2 WO 2004022033 A1 20040318 CAN 140:259115 AN 2004:220183 CAPLUS.
174. T. Chien, Polymer-based transdermal hormone delivery systems, US Pat. Appl. Publ. 2004, 18 pp., Cont.-in-part of US Ser. No. 130,913. CODEN: USXXCO US 2004053901 A1 20040318 CAN 140:259104 AN 2004:220034 CAPLUS.
175. D. L. Wise, D. J. Trantolo, D. D. Hile, S. A. Doherty, Bioadhesive mucosal delivery system for vaccines to induce mucosal immunity to pathogenic microorganisms, PCT Int. Appl. 2004, 40 pp. CODEN: PIXXD2 WO 2004004654 A2 20040115 CAN 140:117356 AN 2004:41223 CAPLUS.
176. S. S. Feng, L. Mu, K. Y. Win, G. Huang, Nanoparticles of biodegradable polymers for clinical administration of paclitaxel, Curr. Med. Chem. 2004, 11, 413-424.
177. C.-K. Kim, S.-J. Lim, Recent progress in drug delivery systems for anticancer agents, Arch. Pharm. Res. 2002, 25, 229-239.
178. A. Mauro, A. Miglietta, R. Cavalli, C. Bocca, M. Guido, A. Di Sapio, L. Pradotto, D. Schiffer, M. R. Gasco, Enhanced cytotoxicity of paclitaxel incorporated in solid lipid nanoparticles against human glioma cells, Proc. 27th Int. Symp. Controlled Release of Bioactive Mater. 2000, 377-378.
179. R. H. Muller, K. Mader, and S. Gohla, Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art, Eur. J. Pharm. Biopharm. 2000, 50, 161-177.
180. I. Oh, K. Lee, H.-Y. Kwon, Y.-B. Lee, S.-C. Shin, C.-S. Cho, C.-K. Kim, Release of adriamycin from poly(c-benzyl-l-glutamate)/ poly(ethylene oxide) nanoparticles, Int. J. Pharm. 1999, 181 (1), 107-115.
181. J. S. Chawla, M. M. Amiji, Affinity scale between a carrier and a drug in DPI studied by atomic force microscopy, Int. J. Pharm. 2002, 249, 127-138.
182. D. Putnam, J. Kopecek, Polymer conjugates with anticancer activity, J. Adv. Poly. Sci. 1995, 122, (Biopolymers II): 55-123.
183. C. Verdun, P. Couvreur, H. Vranckx, V. Lenaerts, M. Roland, Development of a nanoparticle controlled release formulation for human use, J. Control Release 1986, 3, 205-210.
184. K. Na, K.-H. Park, S. W. Kim, Y. H. Bae, Selfassembled hydrogel nanoparticles from curdlan derivatives: characterization, anti-cancer drug release and interaction with a hepatoma cell line (HepG2), J. Control Release 2000, 69, 225-236.
185. S. Choi, W.-S. Kim, J.-H. Jim, Surface modification of functional nanoparticles for controlled drug delivery, J. Disp. Sci. Techn. 2003, 24, 475-487.
186. H. S. Yoo, T. G. Park, In vitro and in vivo antitumor activities of nanoparticles based on doxorubicin-PLGA conjugate. Book of abstracts, 219th ACS National Meeting, San Francisco, March 26-30, Poly-514, 2000.
187. T. Park, "Bioconjugation of Biodegradable Poly(lactic/glycolic acid) to Protein, Peptide, and Anti-Cancer Drug: An Alternative Pathway for Achieving Controlled Release from Micro- and Nanoparticles," in the book "Polymeric drugs and drug delivery systems" Edited by R. M. Ottenbrite and S. W. Kin, 2001, 101-114.
188. H. S. Yoo, J. E. Oh, K. H. Lee, and T. G. Park, Biodegradable nanoparticles containing doxorubicin- PLGA conjugate for sustained release, Pharm. Res. 1999, 16, 1114-1118.
189. K. J. Kim and Y. Byun, Controlled release of all-trans-retinoic acid from PEGylated gelatin nanoparticles by enzymatic degradation, Biotechn. Biopro. Eng. 1999, 4 (3), 215-218.
190. N. Kun, B. You Han, Self-assembled hydrogel nanoparticles responsive to tumor extracellular pH from pullulan derivative/sulfonamide conjugate: characterization, aggregation, and adriamycin release in vitro, Pharma Res. 2002, 19, 681-688.
191. F. Yoshinobu, I. Hideki, T. Hiroyuki, S. Futoshi, M. Masahito, W. Testuya, 2nd Proc Int Conf Process Mater Properties, San Francisco, 2000.
192. S. Sershen, S. Westcott, N. Halas, J. West, Temperature-sensitive polymer-nanoshell composites for photothermally modulated drug delivery, 27th Proc. Int. Symp. Control Release Bio. Mater. 2000, pp. 201-202.
193. A. K. Larsen, A. E. Escargueil, A. Skladanowski, Resistance mechanisms associated with altered intracellular distribution of anticancer agents, Pharmacol. Ther. 2000, 88, 217-229.
194. S. Bennis, C. Chapey, P. Couvreur, J. Robert, Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture, Eur. J. Cancer A 1994, 30, 89-93.
195. A. Colin de Verdiere, C. Dubernet, F. Nemati, M. F. Poupon, F. Puisieux, P. Couvreur, Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells, Cancer Chemother. Pharmacol. 1994, 33, 504-508.
196. A. Astier, B. Doat, M. J. Ferrer, G. Benoit, J. Fleury, A. Rolland, R. Leverge, Enhancement of adriamycin antitumor activity by its binding with an intracellular sustainedrelease form, polymethacrylate nanospheres, in U-937 cells, Cancer Res. 1988, 48, 1835-1841.
197. A. C. de Verdiere, C. Dubernet, F. Nemati, E. Soma, M. Appel, J. Ferte, S. Bernard, F. Puisieux, P. Couvreur, Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action, Br. J. Cancer 1997, 76, 198-205.
198. D. Goren, A. T. Horowitz, D. Tzemach, M. Tarshish, S. Zalipsky, A. Gabizon, Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump, Clin. Cancer Res. 2000, 6, 1949-1957.
199. C. Cuvrie, Doxorubicin loaded nanospheres bypass tumor cell multi-drug resistance, Biochem. Pharm. 1992, 44, 509-517.